We wish to describe the omission of adverse event reporting on finerenone in a recently published trial. We suspect that this case illustrates the tip of an iceberg of underreporting of adverse events in clinical trials. We propose as a requirement in clinical trials, to have routine direct reporting by patients for safety monitoring.
